CytRx (CYTR) Misses Q2 EPS by 8c

CytRx (NASDAQ: CYTR) reported Q2 EPS of ($0.27), $0.08 worse than the analyst estimate of ($0.19).

CytRx reported cash and cash equivalents of $55.9 million as of June 30, 2016. Subsequent to the close of the second quarter, CytRx completed a public offering of common stock and warrants that expire one year from issuance for total net proceeds of approximately $18.3 million.

For earnings history and earnings-related data on CytRx (CYTR) click here.

You May Also Be Interested In

• Growth isn't weak enough to truly undercut inflation pressures - BMO
• MetroCity Bankshares, Inc. (MCBS) Tops Q1 EPS by 4c
• Procter & Gamble (PG) revenue falls short of expectations, raises full-year earnings guidance